Indevus Pharmaceuticals, Inc. has announced that it has entered into a co-promotion and licensing agreement with PLIVA d.d. through its specialty branded subsidiary,
Pfizer has announced that the U.S. Food and Drug Administration has approved its cholesterol-lowering therapy Lipitor? (atorvastatin calcium) for the prevention of cardiovascular disease by reducing he
The common perception that if medication is natural then it must be safe has recently come under fire from a researh by a Consumer Reports magazine. The consumer publication found a dozen herbal supplements, some banned in Asia, Europe
The Food and Drug Administration has announced the approvals of Epzicom (abacavir/lamivudine) and Truvada (tenofovir disoproxil/emtricitabine), two fixed-dose combination treatments for HIV-1 infection.
The U.S. Food and Drug Administration has approved Cymbalta? (duloxetine HCl; pronounced SIM-BALL-TA), judging it a safe and effective treatment for major depressive disorder, Eli Lilly and Company have
A Lawrence company that uses patented technology created at the University of Kansas to improve the effectiveness of drugs has won a $100,000 National Institutes of Health grant to support further testi
Sales of the herbal stimulant ephedra become illegal in the United States on Monday, barring a last-minute reprieve from a federal judge.The Associated Press reports that the maker of one ephedra supplement called Stacker 2, NVE Pharmaceuticals o
Since the release of President George W. Bush's Emergency Plan for AIDS Relief, the U.S. global AIDS coordinator and former CEO of Eli Lilly, Randall Tobias, and other Bush administration officials have made public remarks that question the quality of g
Poised on the brink of phenomenal growth, the oligonucleotides market offers a plethora of opportunities to the enterprising investor. Recent analysis by Frost & Sullivan estimates that the total
Pharmaceutical companies seeking to design more effective cancer chemotherapy agents may have an easier road ahead than was previously believed. A team of researchers, led by a scientist with the U.S. Department of Energy's
These molecules are part of InterMune's robust HCV protease inhibitor program and demonstrate promising potency, bioavailability and metabolic stability in preclinical models. The data were presented at the 55th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) being held in Boston this week.
According to the Centers for Disease Control an estimated 3.9 million (1.8%) Americans have been infected with HCV, of whom 2.7 million are chronically infected, and the prevalence of chronic HCV is increasing. Currently available therapies are insufficient, creating a need for the development of novel therapeutic approaches. Protease inhibitors represent a promising class of drugs for HCV, and the HCV NS3/4 protease is an attractive drug target because of its involvement in viral replication and suppressive effects on host response to viral invasion.
InterMune and Array BioPharma scientists worked in collaboration to discover novel small molecule inhibitors of the HCV NS3/4 protease. Compounds were designed using computational modeling techniques and optimized to achieve high potency. Preclinical plasma pharmacokinetic analysis following intravenous and oral administration was then used in conjunction with other in vitro assays and stability studies to optimize the compounds.
"We have discovered highly potent, metabolically stable, orally available small molecule inhibitors of the HCV NS3/4 protease," said Lawrence Blatt, Ph.D., Senior Vice President of Preclinical and Applied Research at InterMune, who presented the data. "Our preclinical data provide us with the rationale to further test these compounds with the goal of selecting the most appropriate candidate to take into the clinic for development as a treatment for patients with HCV."
In addition, InterMune and Array BioPharma announced the extension of their collaboration, which has focused on the discovery and development of small molecule drugs directed against HCV since 2002. Under this extension, Array will perform process research and cGMP scale-up through Phase I clinical trials of drug candidates resulting from the program. In addition, Array will create second-generation compounds as back-up candidates for the program.
"We are very excited by the progress we have made advancing our novel small molecule program and as a result we have extended our collaboration with Array BioPharma. This extended agreement provides a valuable opportunity to continue the development of novel HCV inhibitors, which we believe may one day prove to be an important component of treatment for HCV patients," said Dan Welch, Chief Executive Officer and President of InterMune. "In addition to our protease inhibitor program, we are advancing our robust and late stage HCV pipeline and growing our marketed brand, Infergen(R) (interferon alfacon-1) for HCV."
http://www.intermune.com/